anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/AU90/00183 Sec. 371 Date Dec. 27, 1991 Sec. 102(e) Date Dec. 27, 1991 PCT Filed May 7, 1990 PCT Pub. No. WO90/13299 PCT Pub. Date Nov. 15, 1990.The present invention relates to a method of enhancing implantation of an embryo within the uterus of a female mammal. The method comprises administering an amount of a PAF antagonist, effective to enhance implantation, to the mammal. The invention also relates to a method of increasing the level of PAF around an embryo in the uterus of a female mammal by administering an amount of a PAF antagonist sufficient to inhibit PAF catabolism. Desirably the PAF antagonist is administered together with PAF or a homologue or analogue thereof. The invention also provides compositions comprising a PAF antagonist together with PAF or a homologue or analogue thereof, and a process for preparing the same.
Disclosed is a method for execution by a server for connecting people with service providers in real-time. The server maintains a set of rules for connecting people with service providers. The server receives, from a first client computing device over a network, a request message having personal information identifying at least a personal issue. The server assesses the personal information against the set of rules to identify service providers that can address the personal issue. Next, for a first subset of service providers, the server sends offer messages and waits for an acceptance message. However, if no acceptance message is received within a timeout period, for a subsequent subset of service providers, the server sends offer messages and waits for an acceptance message. Advantageously, if no match can be established with the first subset, it may be possible to establish a match with the subsequent subset.
BACKGROUND: Identifying individuals with mild cognitive impairment (MCI) at risk of progressing to Alzheimer's disease (AD) provides a unique opportunity for early interventions. Therefore, accurate and long-term prediction of the conversion from MCI to AD is desired but, to date, remains challenging. Here, we developed an interpretable deep learning model featuring a novel design that incorporates interaction effects and multimodality to improve the prediction accuracy and horizon for MCI-to-AD progression.
METHODS: This multi-center, multi-cohort retrospective study collected structural magnetic resonance imaging (sMRI), clinical assessments, and genetic polymorphism data of 252 patients with MCI at baseline from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Our deep learning model was cross-validated on the ADNI-1 and ADNI-2/GO cohorts and further generalized in the ongoing ADNI-3 cohort. We evaluated the model performance using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and F1 score.
RESULTS: On the cross-validation set, our model achieved superior results for predicting MCI conversion within 4 years (AUC, 0.962; accuracy, 92.92%; sensitivity, 88.89%; specificity, 95.33%) compared to all existing studies. In the independent test, our model exhibited consistent performance with an AUC of 0.939 and an accuracy of 92.86%. Integrating interaction effects and multimodal data into the model significantly increased prediction accuracy by 4.76% (P = 0.01) and 4.29% (P = 0.03), respectively. Furthermore, our model demonstrated robustness to inter-center and inter-scanner variability, while generating interpretable predictions by quantifying the contribution of multimodal biomarkers.
CONCLUSIONS: The proposed deep learning model presents a novel perspective by combining interaction effects and multimodality, leading to more accurate and longer-term predictions of AD progression, which promises to improve pre-dementia patient care.
PGT-A and freeze-all (by vitrification) of day 5 and/or day 6 and/or day 7 blastocyst(s) and subsequent transfer of euploid or mosaic (≤80%) blastocysts in FET cycles. Luteal phase supplementation (LPS) will be administered according to the participating clinics standard practice.
Hemolysis persists as a common and serious problem for neonatal patients on extracorporeal membrane oxygenation (ECMO). Since the cannula within the ECMO circuit is associated with hemolysis-inducing shear stresses, real-world internal fluid flow measurements are urgently needed to understand the mechanism and confirm computational estimates. This study appears to be the first experimental study of fluid flow inside commercial ECMO dual-lumen cannulas (DLCs) and first particle image velocimetry (PIV) visualization inside a complicated medical device. The internal geometries of four different opaque neonatal DLCs, both atrial and bicaval positioning geometries each sized 13 Fr and 16 Fr, were replicated by three-dimensional printing clear lumen scaled-up models, which were integrated in a circuit with appropriate ECMO flow parameters. PIV was then used to visualize two-dimensional fluid flow in a single cross section within the models. An empirical model accounting for shear stress and exposure time was used to compare the maximum expected level of hemolysis through each model. The maximum measured peak shear stress recorded was 16±2 Pa in the top arterial bicaval 13 Fr model. The atrial and 16 Fr cannula models never produced greater single-pass peak shear stress or hemolysis than the bicaval and 13 Fr models, respectively, and no difference was found in hemolysis at two different flow rates. After 5 days of flow, small DLC-induced hemolysis values for a single pass through each cannula were modeled to linearly accumulate and caused the most severe hemolysis in the bicaval 13 Fr DLC. Engineering and clinical solutions to improve cannula safety are proposed.
BACKGROUND: Caudal block is a commonly used method of postoperative pain management in children. However, single shot caudal block has shorter duration of analgesia that can be extended by addition of adjuncts like opioids, clonididine, and dexmedetomidine along with local anesthetics. Recently, dexmedetomidine has been used as an adjunct for prolonging the duration of analgesia. This study aimed to find out prevalence of the caudal block and the duration of analgesia with dexmedetomidine adjunct among children undergoing lower abdominal surgeries.
METHODS: A cross-sectional, observational study was conducted among the children admitted to the tertiary care children hospital of Nepal during the period of six months. Children of age 2 to 7 years, who had undergone lower abdominal surgeries under general anesthesia were enrolled in the study. We observed the prevalence of the caudal block and duration of analgesia of caudal dexmedetomidine with ropivacaine Results: Throughout the study period, 449 children were posted for lower abdominal surgeries. Out of which 226 children (50.03%) received caudal block. Among the caudal block, 51 children (22.56%)) were administered ropivacaine with dexmedetomidine, 45 children (19.91%) received ropivacaine alone, 43 children (19.02%) were given bupivacaine alone, 46 children (20.35%) received a combination of bupivacaine and fentanyl, and 41 children (18.14%) received bupivacaine and dexmedetomidine. Dexmedetomidine with ropivacaine provides 840.35±14.97 minutes of postoperative pain relief.
CONCLUSIONS: The prevalence of the caudal block was 50.03%, and the combination of Dexmedetomidine with ropivacaine provides longer duration of postoperative analgesia.
BACKGROUND: The study aimed to translate and validate the Prolonged Grief Disorder (PG-13) scale from English into Urdu language. This involved examining its psychometric properties, evaluating its factor structure and assessing both convergent and discriminant validity. The study was conducted within the cultural context of Pakistan and focused on the assessment of manifestations of grief, including symptoms of prolonged grief, in adolescents with mild-to-moderate intellectual disability (ID). The PG-13 scale was selected for this study due to its demonstrated accuracy in measuring prolonged grieving symptoms in bereaved population.
METHOD: A total of 140 adolescents, aged 10-19 years according to the World Health Organization (WHO) 2018 criteria, were selected from 14 cities in Pakistan. These participants had lost loved ones within the time span of the last 4 years. The WHO (2018) guidelines for translation, adaptation, and validation were followed.
RESULTS: The findings suggest that the translated and validated PG-13 scale has adequate psychometric properties, with Cronbach alpha coefficient of .97. Confirmatory factor analysis supports a single-factor structure for the scale, with factor loadings ranging from .80 to .95.
CONCLUSION: The PG-13 Urdu version is a reliable and validated scale available for assessing grieving symptoms in the Pakistani context.
PURPOSE: This report provides the experimental, clinical, theoretical, and historical background that motivated a patented transitional intervention and its implementation and evaluation in a field trial for mitigation of debilitating loudness-based hyperacusis (LH).
BACKGROUND AND RATIONALE: Barriers for ameliorating LH, which is differentiated here from other forms of hyperacusis, are delineated, including counterproductive management and treatment strategies that may exacerbate the condition. Evidence for hyper-gain central auditory processes as the bases for LH and the associated LH-induced distress and stress responses are presented. This presentation is followed by an overview of prior efforts to use counseling and therapeutic sound as interventional tools for recalibrating the hyper-gain LH response. We also consider previous efforts to use output-limiting sound-protection devices in the management of LH. This historical background lays the foundation for our transitional intervention protocol and its implementation and evaluation in a field trial.
CONCLUSIONS: The successful implementation and evaluation of a transitional intervention, which we document in the outcomes of a companion proof-of-concept field trial in this issue, build on our prior efforts and those of others to understand, manage, and treat hyperacusis. These efforts to overcome significant barriers and vexing long-standing challenges in the management and treatment of LH, as reviewed here, are the pillars of the transitional intervention and its primary components, namely, counseling combined with protective sound management and therapeutic sound, which we detail in separate reports in this issue.
The invention relates to targeted nanometer photosensitizer for photodynamics deep tumor therapy and a preparing method thereof. According to the preparing method, protein, or polypeptide or amino acid is used for reacting with a soluble copper salt solution, and the monovalence protein chelated targeted nanometer photosensitizer or the polypeptide-copper chelated targeted nanometer photosensitizer or the amino acid-copper chelated targeted nanometer photosensitizer is obtained after reduction. Under excitation of X rays with the dosage much lower than a general radiotherapy dosage, the targeted nanometer photosensitizer can generate strong fluorescence and has a photodynamics therapy effect on tumors. The targeted nanometer photosensitizer is small in particle size, good in water solubility, small in toxic and side effect and capable of being endocytosed by deep tumor cells easily. The X rays serve as an excitation light source of the targeted nanometer photosensitizer, the therapy efficiency is high, and the problems that existing photodynamics therapy cannot be carried out on the deep tumors, and skin phototoxicity is caused can be solved. Reaction conditions of the photosensitizer are moderate, and the photosensitizer can be industrially manufactured, achieves energy conservation and environment protection, can promote the silkworm breeding and mulberry growing industrial chain to develop in the high value-added industry direction, and has good economic benefits, social benefits and ecological benefits.
PURPOSE:To obtain a banaba (Lagerstroemia speciosa) leaf extract having excellent preservability and usable as a drink or food by industrially extracting banaba leaf under prescribed condition and using the extract as freeze-dried powder or as a drink, to provide a method for using the extract and to provide an antidiabetic agent containing the extract as a component. CONSTITUTION:Dried and crushed banaba leaf is extracted with hot water and filtered to obtain a hot-water extract liquid and a residue. The residue is extracted with methanol and filtered to obtain a methanol extract liquid. The hot-water extract and the methanol extract are separately sterilized in an autoclave and freeze-dried to obtain the objective banaba leaf extract powder. The extract powder can be mixed into a food or drink after diluting to a concentration of about 0.1-10%. It is also effective as an antidiabetic agent.
The invention provides methods to determine the cancer prognosis of subjects and to adapt the treatment protocol of subjects having or susceptible to cancer. The method comprises steps of determining in vitro the genotype of a subject at a polymorphism in the C3-ITGAM (integrin alpha M) axis, making a cancer prognosis of the subject based on said genotype and selecting an anti-cancer treatment for the subject. ITGAM (or CD 11b) may have a polymorphism at position 425 in the domain containing Asp398 to Thr451, and the C3 (complement component 3) may have a polymorphism at position 80. A therapeutic antibody (rituximab) may then be administered accordingly. Determining the polymorphisms may utilise RNA hybridisation, a specific affinity reagent, enzyme digestion or PCR amplification. Specifically the cancer may be non-Hodgkin's lymphoma. Methods of treatment are also provided.
The invention discloses traditional Chinese medicine for treating diabetes. Huidouba and guava leaves as used as main components, and components including cinnamomum cassia, Chinese yam rhizome, dictyophora indusiata, astragalus membranaceus and the like are mixed into the main components for preparing the traditional Chinese medicine. The traditional Chinese medicine is prepared from the following components in a recipe in percentage by weight: 2 percent to 7 percent of dictyophora indusiata, 2 percent to 5 percent of cinnamomum cassia, 9 percent to 15 percent of gardenia, 8 percent to 15 percent of guava leaves, 5 percent to 15 percent of zaocys dhumnade, 5 percent to 8 percent of angelica dahurica, 3 percent to 9 percent of fructus citri, 10 percent to 16 percent of Huidouba, 8 percent to 20 percent of Chinese yam rhizome, 5 percent to 10 percent of kudzu root leaves, 8 percent to 12 percent of astragalus membranaceus and 4 percent to 10 percent of corn stigma. During the medicine taking, firstly, the Huidouba is treated through micro washing and is then mixed with other components; after the components are decocted and boiled for 20 minutes in an earthen pot, liquid is taken; one dose is taken every day in 2 to 3 times; or the Huidouba is treated through micro washing and is then boiled to the boiling state for 15 minutes in the earthen pot; and the liquid is taken; and the rest medicine is made into pills or granules to be taken at the same time. The traditional Chinese medicine composition has the main function of controlling, relieving and treating the diabetes; the curative effect taking speed is high; and the diabetes cannot easily reoccur. The traditional Chinese medicine has low dependency and small toxic or side effects; the aging of insulin cells can be reduced; and the induction of various inductions can be prevented.
FIELD: medicine. SUBSTANCE: method involves applying preparative procedures before implanting normal intestinal microflora preparations containing living organisms. Cleaning enemas containing neutral electrically activated anolyte solution of 6-6.5 pH are applied during 2 days. Intestine enteroclysis is carried out during the next 5 days with catholyte solution of 9-9.5 pH. The solution temperature is equal to 18-20 C in the cases of hypomotor disease form and 35-40 C in the cases of hypermotor disease form. Cleaning catholyte solution enema being done, electrically activated aqueous solutions are to be rectally introduced through catheter. The solutions contain Ca ++  ions in the cases of hypermotor disease forms, and C ++ ,K + ,Mg ++  ions in the cases of hypomotor disease forms. EFFECT: enhanced effectiveness of treatment; favorable conditions increasing intestine mucosa absorption capability. 2 cl, 1 tbl
Advise patients:

  * Accidental ingestion of diphenoxylate hydrochloride and atropine sulfate tablets in children, especially in those less than 6 years of age, may result in severe respiratory depression or coma. Instruct patients to take steps to store diphenoxylate hydrochloride and atropine sulfate tablets securely and out of reach of children, and to dispose of unused diphenoxylate hydrochloride and atropine sulfate tablets (see WARNINGS).
  * To take diphenoxylate hydrochloride and atropine sulfate tablets at the prescribed dosage. Use of a higher than prescribed dosage may include opioid and/or anticholinergic effects (see OVERDOSAGE). Report to a healthcare facility if they develop anticholinergic symptoms such as hyperthermia, flushing, tachycardia, tachypnea, hypotonia, lethargy, hallucinations, febrile convulsion, dry mouth, mydriasis or opioid symptoms such as progressive CNS and respiratory depression, miosis, seizures, or paralytic ileus.
  * Diphenoxylate hydrochloride and atropine sulfate tablets may produce drowsiness or dizziness. Concomitant use of alcohol or other drugs that also cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, and muscle relaxants) may increase this effect. Inform patients not to operate motor vehicles or other dangerous machinery until they are reasonably certain that diphenoxylate hydrochloride and atropine sulfate tablets does not affect them adversely. 
  * To use fluid and electrolyte therapy, if prescribed along with diphenoxylate hydrochloride and atropine sulfate tablets, as instructed by their healthcare provider.
  * Clinical improvement of diarrhea is usually observed within 48 hours. If clinical improvement is not seen within 10 days, discontinue diphenoxylate hydrochloride and atropine sulfate tablets and contact their healthcare provider.
In one aspect, the invention relates to method and systems for automating medical data processing and counseling. A method may include receiving a selection of a condition associated with a plurality of diagnosis possibilities for a patient. The method may further include displaying candidate treatment options based upon, at least in part, the condition associated with the plurality of diagnosis possibilities for the patient. The method may also include receiving a selection of a candidate treatment option from the candidate treatment options displayed and a regimen associated with the candidate treatment option selected. The method may additionally include determining a diagnosis for the patient based upon, at least in part, the condition associated with the plurality of diagnosis possibilities for the patient, the candidate treatment option, and the regimen. The diagnosis may be one of the plurality of diagnosis possibilities for the patient.
When treatment with oral phenytoin is not possible, IV phenytoin can be substituted for oral phenytoin at the same total daily dose. Phenytoin capsules are approximately 90% bioavailable by the oral route. Phenytoin is 100% bioavailable by the IV route. For this reason, serum phenytoin concentrations may increase modestly when IV phenytoin is substituted for oral phenytoin sodium therapy. The rate of administration for IV phenytoin should be no greater than 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients.

When intramuscular administration may be required, a sufficient dose must be administered intramuscularly to maintain the serum level within the therapeutic range. Where oral dosage is resumed following intramuscular usage, the oral dose should be properly adjusted to compensate for the slow, continuing IM absorption to minimize toxic symptoms [see Clinical Pharmacology (12.3)].

Serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form. Phenytoin Sodium Injection is formulated with the sodium salt of phenytoin. Because there is approximately an 8% increase in drug content with the free acid form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa.
Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with complete response, partial response, or stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray imaging throughout the trial. Patients may CT as clinically indicated. Patients also undergo blood sample collection and may optionally undergo tissue biopsy during screening and on the trial.
The invention relates to the technical field of traditional Chinese medicines and provides a traditional Chinese medicine composition for treating child anorexia according to a child anorexia understanding mechanism of the traditional Chinese medicine. The traditional Chinese medicine composition comprises, by weight, 5-7 parts of oriental wormwood, 4-6 parts of rhizoma atractylodis, 4-8 parts of dandelion, 3-7 parts of herba eupatorii, 1-3 parts of round cardamom fruits and 8-12 parts of coix seeds. The traditional Chinese medicine composition is decocted through water and the decoction is drunk twice every day. A treatment course comprises seven days. The traditional Chinese medicine composition utilizes easily available raw materials and has curative effects and no side effect. A test on hundreds of child anorexia patients proves that the traditional Chinese medicine composition has an effective rate of 92.3%.